Branched-chain amino acids (BCAAs) comprise the essential amino acids leucine, isoleucine, and valine. BCAA metabolism is unique in that it bypasses first-pass metabolism through the liver. BCAAs are instead taken up by peripheral tissues and metabolized locally. BCAAs are well recognized for their robust activation of of mammalian target of rapamycin complex 1 (mTORC1) critically involved in cell metabolism, growth, and proliferation. BCAAs can also provide key intermediates to fuel the tricarboxylic acid cycle and thereby serve as energy buffers during periods of low energy availability. Beyond their reputation as anabolic drivers of muscle accretion, BCAAs additionally engage in immune regulation, glucose control, and neurotransmitter synthesis.
Following ingestion, BCAAs are broken down in the small intestine and absorbed through the L-type amino acid transporter 1 (LAT1). They enter the circulation to be distributed amongst various tissues, particularly that of the skeletal muscle, adipose, liver, and myocardium. They are largely catabolized locally in the mitochondria, first being transaminated by branched-chain aminotransferase (BCAT) to generate branched-chain α-keto acids (BCKAs). The second, rate-limiting step involves oxidative decarboxylation by branched-chain α-keto acid dehydrogenase complex (BCKDH) to produce leucine, isoleucine, and valine. Circulating BCAAs stimulate glucose and corresponding insulin release, the latter of which promotes tissue uptake, suppresses protein breakdown and associated BCAA release, and upregulates BCKDH to expedite BCAA catabolism.
BCAAs, especially leucine, potently galvanize mTORC1, resulting in downstream phosphorylation of S6K1 and 4E-BP1. This triggers mRNA translation and protein synthesis. Both leucine and mTORC1 additionally act as signals to halt autophagy. Leucine inhibits the ubiquitin-proteasome system, while mTORC1 prompts phosphorylation of the pro-autophagy factors ULK1, TFEB, and Beclin-1. BCAA supplementation has been observed to overcome the anabolic resistance noted with aging, thereby preserving muscle mass in older populations, as well as in the pathological conditions of sarcopenia, liver cirrhosis, chronic kidney disease, and cancer cachexia.
Liver cirrhosis is correlated with a disproportionate ratio of aromatic to branched-chain amino acids, the so-called Fischer ratio. BCAA supplementation in these situations can remedy the Fischer ratio and successfully compete with aromatic amino acids for blood-brain barrier transport. Such an effect attenuates hepatic encephalopathy symptoms and may enhance neurotransmitter balance, especially that of tryptophan and serotonin. Poor hepatic detoxification induces the rerouting of ammonia to the skeletal muscle, where BCAAs can participate in ammonia metabolism. Furthermore, BCAAs may rescue hepatocyte atrophy and amplify liver regeneration due to their interaction with mTORC1. BCAAs also boost serum albumin levels to effectively reduce ascites and edema.
Moreover, BCAAs provide the necessary substrates for lymphocyte performance and dendritic cell function. Immunoglobulins produced by B lymphocytes necessitate a substantial supply of amino acids. The role of BCAAs in immune cell function indicates an application for BCAA supplementation during times of acute illness in an effort to enhance T and B lymphocyte activity. BCAAs have been purported to improve mitochondrial function and cellular energy metabolism, potentially conferring anti-inflammatory and anti-oxidant benefits. In spite of the range of situations in which BCAAs may exert a positive impact, chronic over-activation of the pathways they influence can also be detrimental to long term health.
Hereditary maple syrup urine disease (MSUD) is characterized by toxic accumulation of BCAAs and BCKAs. MSUD induces neurotoxicity and metabolic acidosis, serving as a prime example of the severe consequences of BCAA buildup. Disruption of BCAA catabolism elicits BCKA accrual, resulting in inhibition of insulin-stimulated Akt phosphorylation. Glucose uptake and mitochondrial oxygen consumption are subsequently impaired, exacerbating glucose excursions and insulin resistance. Chronically high ingestion and/or circulation of BCAAs has thus been proposed as a biomarker of insulin resistance.
Insulin resistance in turn decelerates peripheral uptake of circulating BCAAs and undermines their oxidation in the mitochondria. Incomplete BCAA oxidation facilitates accumulation of both BCAAs and branched-chain acylcarnitines (BCACs). This buildup impairs fatty acid oxidation, hyperactivates the mTORC1/S6K1 pathway, and potentiates oxidative stress and mitochondrial membrane dysfunction. Hyperactivation of mTORC1/S6K1 amplifies insulin resistance via downstream serine phosphorylation of insulin receptor substrate-1 (IRS-1) which hinders insulin signal transduction. Redox imbalance feeds forward to trigger NF-kB and the NLRP3 inflammasome, setting off an inflammatory cascade that further interferes with insulin action.
The mitochondria serve as the only site of BCAA oxidation, highlighting their dysfunction as a critical inflection point of disrupted BCAA metabolism. Metabolic deterioration is a consistent finding amongst cohorts displaying alterations in BCAA concentrations. While physiological levels of BCAAs support mitochondrial biogenesis via AMPK and PGC-1α signaling, chronic elevations of circulating BCAAs exert the opposite effect. Mitochondrial oxidation becomes notably diminished, as does mitochondrial regenerative capacity. Obese individuals as well as those with cardiometabolic disease exhibit poor BCAA catabolism in conjunction with reduced BCKDH activity. Pro-inflammatory adipose tissue has been proposed as an instigator of such an effect. BCAA ingestion elicits secretion of high mobility group box 1 (HMGB1), a metabolism-related protein that incites adipose M1 macrophage polarization. Inflamed adipose subsequently releases TNF-α and IL-6 which diminish BCKDH and BCAT activity.
Inadequate BCAA catabolism and ensuing intermediate accretion aggravate mitochondrial reactive oxygen species production and mitochondrial stress, cultivating a vicious cycle. Mitochondrial impairment, reactive oxygen species, and intermediate byproducts of BCAA breakdown can all behave as damage-associated molecular patterns (DAMP) that spur inflammation. Cytokines including TNF-α, IL-6, and monocyte chemoattractant protein-1 (MCP-1) lead to IRS-1 serine phosphorylation, insulin resistance, lipid accumulation, and reduced BCAA catabolic capacity. These effects compound to magnify metabolic dysfunction that culminates in promotion of atherosclerosis, metabolic-associated steatotic liver disease (MASLD), diabetes, and other metabolic disorders.
In cardiometabolic disease, excessive BCAA concentrations drive mTROC1, which provokes proliferation of vascular smooth muscle cells and formation of macrophage foam-cells. A decline in BCAA catabolism and buildup of intermediates such as 3-hydroxyisobutyrate (3-HIB) accelerates trans-endothelial fatty acid transport, skeletal muscle fatty acid uptake, and ectopic lipid aggregation. Subsequent lipotoxicity compromises skeletal muscle metabolism and glucose uptake, driving glucose excursions and insulin resistance. In the medium of oxidative stress and adipose M1 macrophage polarization, NF-kB and NLRP3 inflammasome stimulation instigate cytokine, chemokine, and adhesion molecule release. Inflammation in turn represses BCAA catabolism, establishing a positive feedback loop.
Early and non-cirrhotic MASLD/MASH is associated with a rise in BCAA levels. By contributing to insulin resistance, excessive BCAAs potentiate adipose lipolysis and hepatic lipogenesis. Meanwhile, mTORC1 hyperactivity augments SREBP-1c and fatty acid synthase expression, and circulating BCAAs supply the requisite carbons for fatty acid synthesis. BCAA catabolic intermediates also block fatty acid oxidation and hinder mitochondrial oxidation.
Severe escalations in BCAAs may facilitate a pro-tumorigenic environment via metabolic and mitochondrial dysfunction, oxidative stress, inflammation, mTORC1 activation, and provision of amino acids for rapid growth and proliferation. BCAAs serve the vital roles of supporting protein synthesis, nucelotide and non-essential amino acid synthesis, and energy production. Tumor cells have been demonstrated to robustly reprogram BCAA metabolism, at times suppressing BCAA catabolic enzyme activity. The consequent rise in BCAA levels drives mTORC1 stimulation. BCAT1 has also been found to be increased, boosting glutamate availability. An upregulation of BCAT1 may enhance nitrogen availability and mTORC1 signaling to promote biosynthesis of cell components.
Additionally, BCAAs may exacerbate renal insufficiency by expediting ammonia toxicity and increasing the likelihood of insulin resistance and metabolic syndrome. BCAAs may impair autophagy while facilitating oxidative stress and mitochondrial impairment, as well as alter neurotransmitter balance, potentially playing a role in neurodegenerative disease. Collectively, the capacity of excess BCAAs to instigate insulin resistance, mitochondrial impairment, oxidative stress, mTORC1 hyperactivation, downstream inflammatory cascades, metabolic inflexibility, and gut dysbiosis presents sincere concerns to long term health.
Certain bacterial taxa of the gut microbiome can synthesize BCAAs from precursors. Prevotella copri and Bacteroides vulgarus have been identified as two of the predominant BCAA-metabolizing bacterial strains. The gut microbiome is also responsible for the uptake and degradation of BCAAs. Proliferation of Faecalibacterium prausnitzii can attenuate BCAA levels due to its preference for BCAA internalization. Moreover, Faecalibacterium prausnitzii is recognized as a short-chain fatty acid-generating species. Short-chain fatty acids released by bacteria following the fermentation of dietary fiber epigenetically modify BCAA metabolism genes, elevating their expression. Dysbiosis has been noted to disrupt BCAA-related metabolic pathways and cause BCAA accumulation. BCAA supplementation disturbs microbial populations, diminishing Lacticaseibacillus paracasei and Bifidobacterium dentium and altering gut hormone levels of GLP-1, CCK, and PYY.
In summary, research indicates that caution should be exercised when ingesting high levels of BCAAs. BCAA application may be beneficial in the context of elite athletes and specific chronic and acute disease states. The dose-response relationship of BCAA consumption displays considerable inter-individual variability and is non-linear in nature. Genetic polymorphisms, health status, and activity levels are important considerations prior to recommending BCAA supplementation. Insulin sensitivity is a key determinant of BCAA response, while mitochondrial performance, underlying inflammation, nutritional status, microbiome composition, and disease type and stage are also critical variables.
Li J, Chen H, Zhou Y, et al. Angel or demon? The dual role of branched-chain amino acids in chronic inflammatory and injury-related diseases. Front Immunol. 2026;17:1778455. Published 2026 Apr 22. doi:10.3389/fimmu.2026.1778455